Single-agent HD-DMX treatment for 4 days decreased the plasma IL-16 level and downregulated mRNA expression of IL-16, caspase-3, and T-bet in ITP patients PBMCs. This evidence concerns the gene CASP3 and autoimmune thrombocytopenic purpura.